- Year 2017
- Sant Joan Despí Moisès Broggi Hospital
Phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven study to evaluate the efficacy and safety of finerenone, associated with standard treatment, in reducing cardiovascular morbidity and mortality in patients with diabetes Mellitus Type 2 and clinical diagnosis of diabetic nephropathy